UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000002220
Receipt number R000002726
Scientific Title Use of accelerator Mass Spectrometry to measure the pharmacokinetics and metablites analysis of C14-labled tolbutamide
Date of disclosure of the study information 2009/07/23
Last modified on 2009/11/05 16:17:50

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Use of accelerator Mass Spectrometry to measure the pharmacokinetics and metablites analysis of C14-labled tolbutamide

Acronym

Use of accelerator Mass Spectrometry to measure the pharmacokinetics and metablites analysis of C14-labled tolbutamide

Scientific Title

Use of accelerator Mass Spectrometry to measure the pharmacokinetics and metablites analysis of C14-labled tolbutamide

Scientific Title:Acronym

Use of accelerator Mass Spectrometry to measure the pharmacokinetics and metablites analysis of C14-labled tolbutamide

Region

Japan


Condition

Condition

healthy volunteer

Classification by specialty

Not applicable

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To measure tolbutamide pharmacokinetics and human metabolites by C14-labeled tolbutamide(100µg, 7400Bq) oral administration.
Parent and metabolites of tolbutamide are separeted and detected by AMS and metabolites structure analysis is evaluated by LC/MS/MS. SNPs effect on those profiles is also analyzed.

Basic objectives2

Pharmacokinetics

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

general feasibility of microdose clinical trail using AMS based on evaluated data compared with known data and parameters.

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

oral administration of C14-tolbutamide

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

45 years-old >

Gender

Male

Key inclusion criteria

the investigators must ensure that all subjects being considerd meet the following inclusion criteria
1)capable to understand and sign the informed consent.
2)20-45 years of age
3)BMI 18.5-25.0
4)good health as determined by physical examination, vital signs and laboratory tests.
5)CYP2C9 SNP's classified in EM(*1/*1) or IM(*1/*3)

Key exclusion criteria

the investigators must ensure that all subjects being considered meet the following exclusion criteria or conditions
1)diabetes or blood glucose abnormality
2)dysemia
3)history of cardiac disease
4)impairmant of liver or kidney functions
5)any medical condition that reqires medical attention
6)recent (past 4 months) participation in other clinical trial and the investigator determines this trial participation inadequate
7)history of allergy to tolbutamide
8)donation of 400mL or more of blood within 3 months prior to participation, donation of 200mL or more of blood within 1 month prior to participation, or donation of component blood within 2 weeks prior to participation
9)positive serologic reaction of syphilis, positive results of HIV test, HBsAg and HCVAb
10)history of multiple and recurning allergies to medicines or food
11)history of drug or alcohol abuse
12)the investigator determines this trial participation inadequate

Target sample size

6


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Setsuo Hasegawa

Organization

Sekino Clinical Pharmacology Clinic

Division name

Sekino Clinical Pharmacology Clinic

Zip code


Address

3-28-3 Ikebukuro, Toshima-ku Tokyo

TEL

03-5396-4505

Email



Public contact

Name of contact person

1st name
Middle name
Last name Kainuma Michiko

Organization

Sekino Clinical Pharmacology Clinic

Division name

Sekino Clinical Pharmacology Clinic

Zip code


Address

3-28-3 Ikebukuro, Toshima-ku Tokyo

TEL

03-5396-4530

Homepage URL


Email



Sponsor or person

Institute

APDD

Institute

Department

Personal name



Funding Source

Organization

APDD

Organization

Division

Category of Funding Organization

Nationality of Funding Organization

JAPAN


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2009 Year 07 Month 23 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2009 Year 07 Month 23 Day

Date of IRB


Anticipated trial start date

2009 Year 07 Month 01 Day

Last follow-up date

2010 Year 03 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2009 Year 07 Month 17 Day

Last modified on

2009 Year 11 Month 05 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002726


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name